Nuvectis Pharma, Inc. (NVCT)
24.49
+0.12
(+0.49%)
USD |
NASDAQ |
Sep 04, 16:00
24.47
-0.02
(-0.08%)
After-Hours: 20:00
Nuvectis Pharma SG&A Expense (TTM) : 9.218M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.218M |
| March 31, 2026 | 9.687M |
| December 31, 2025 | 9.421M |
| September 30, 2025 | 8.843M |
| June 30, 2025 | 8.363M |
| March 31, 2025 | 7.081M |
| December 31, 2024 | 6.929M |
| September 30, 2024 | 7.577M |
| June 30, 2024 | 7.709M |
| March 31, 2024 | 7.519M |
| December 31, 2023 | 7.517M |
| Date | Value |
|---|---|
| September 30, 2023 | 7.297M |
| June 30, 2023 | 7.043M |
| March 31, 2023 | 6.601M |
| December 31, 2022 | 6.007M |
| September 30, 2022 | 4.747M |
| June 30, 2022 | 3.841M |
| March 31, 2022 | 4.466M |
| December 31, 2021 | 3.349M |
| September 30, 2021 | 2.228M |
| June 30, 2021 | 1.716M |
| March 31, 2021 | 0.023M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Decoy Therapeutics, Inc. | 4.096M |
| Unicycive Therapeutics, Inc. | 23.53M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Anika Therapeutics, Inc. | 52.67M |